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For a therapeutic mAb to reach the clinic, the molecule must be produced at an 
appropriate yield and quality, then formulated to maintain efficacy and stability. The 
formation of sub-visible particles (SVPs) can impact on product stability and is 
monitored during formulation development however, the potential of a mAb to form 
such species can be influenced throughout the whole bioprocess. We investigate 
levels of intracellular ER stress perceived by cells, day of mAb harvest and the 
relationship to subsequent product stability of two mAbs (denoted A and B), produced 
in CHO cell lines, as determined by SVP content after accelerated stability studies. 
We show the propensity of mAb A to form SVPs can be predicted by transcript 
expression of biomarkers of cellular ER stress, heavy/light chain transcript and 
polypeptide amounts, and harvest day. Further, mAb A material harvested on day 9 of 
culture was more stable, in terms of SVP formation, than material harvested on day 
13. These data suggest that ER stress perceived by CHO cells during culture can 
reflect the stability of a mAb, and that biomarkers of such stress could help define 
culture harvest time as a tool to control or reduce SVP formation in formulated mAbs.  
Graphical Abstract 
Biotherapeutics are an important class of drugs produced in living cells, with 
monoclonal antibodies (mAbs) representing a large portion of protein based drugs on 
the market. mAb production can be considered of as consisting of three stages: (1) 
cell culture to produce high quantities and quality of mAb material, (2) purification 
to separate the mAb from other cellular compounds, and finally (3) formulation 
development, during which mAb stability is assessed to determine the drug format, 
shelf life and storage conditions. Establishing an appropriate formulation for a mAb is 
essential to ensure product stability and safety however, it is known that parts of the 
bioprocess can negatively impact on mAb quality. Here, the authors report on the link 
between upstream bioprocessing and formulated mAb stability, detailing the impact of 














Chinese hamster ovary (CHO) cells are the expression system of choice for producing 
therapeutic monoclonal antibodies (mAbs) [1, 2] largely due to their ability to undertake 
human-like post-translational modifications and their ability to achieve titres exceeding 10 
g/L [3]. However, in order for a therapeutic mAb to reach the clinic, it is not only necessary 
to produce the molecule at an appropriate yield and quality, but also to develop a product with 
a suitable mode of delivery, dosage and shelf life. Establishing an appropriate formulation is 
therefore key in maintaining the stability and quality of a drug product during storage, whilst 
also ensuring that the dosage is safe and efficacious when administered to patients. 
Soluble aggregation, sub-visible particle (SVP) formation and fragmentation are among a 
range of product quality attributes which are monitored during bioprocessing and formulation 
development. These characteristics are also reported in data packages submitted to regulatory 
authorities as part of drug approval procedures. It has been reported that the presence of 
aggregates and particles in mAb formulations have the potential to cause autoimmune 
responses in patients and can impact on drug safety and activity [4-8]. As a result, the 
monitoring and control of aggregates during fermentation, downstream processing and 
formulation development is important to ensuring the safety and efficacy of mAbs destined 
for use in the clinic. Whilst the formation of subvisible particles may be monitored at 
different stages of the whole bioprocess, the greatest emphasis on monitoring is during 
formulation development. Thus, although mAb stability and propensity to form SVPs can be 
potentially influenced throughout bioprocessing, it is somewhat surprising that there have 
been few studies that look to establish a link between upstream bioprocessing, formulation 
development and SVPs as a measure of product stability. 
The production of a mAb is typically divided into three stages; upstream culturing, 
downstream purification and formulation/fill finish. Traditionally these processes have been 












should be considered as a whole [3, 9, 10], including how upstream and downstream 
processes may impact product quality before the material is provided to the formulation 
scientist. During upstream culturing, endoplasmic reticulum (ER) stress can be induced via 
amino acid or glucose deprivation, high recombinant protein load and the accumulation of 
unfolded/misfolded proteins [11-14]. Such stress is responded to via the activation of the 
unfolded protein response (UPR) and ER associated degradation (ERAD). These pathways 
serve as quality control mechanisms to maintain homeostasis through relaying information 
from the ER lumen to the nucleus, enabling cells to adapt to, remove and prevent the build-up 
of misfolded/unfolded proteins. Alternatively, the UPR will trigger cell death in the event of 
unresolvable stress [15-21]. These quality control mechanisms are often activated in CHO 
cell lines producing high quantities of recombinant material [18, 22, 23], and as a result ER 
stress can impact cell growth and productivity. In turn, such stress may affect protein folding, 
assembly and post translational modifications (such as glycosylation patterns) leading to 
aggregate and/or fragment formation which can compromise product quality and ultimately 
impact the stability of final product [10, 24-26]. Thus, the impact of the bioprocess on product 
quality should be considered when material is provided to the formulation scientist. 
Previous studies have reported ER stress experienced by cells during culture through the use 
of mRNA biomarker profiling. Such studies have demonstrated that CHO cells grown under 
both batch [27, 28] and fed-batch [12] conditions are under increased stress as cultures 
progress. Surprisingly however, the relationship between increased culture stress and the 
stability of formulated mAbs has, to date, not been examined. Here, we use two industrial 
CHO cell lines expressing different mAbs to determine the ER stress response profile under 
fed-batch and batch conditions. Subsequently, we investigate the stability of the formulated 
mAbs harvested during different stages of culture, and therefore produced when cells are 
experiencing different levels of stress, by monitoring soluble aggregate, fragment and SVP 
formation. Our studies show that the two mAb producing cell lines elicit differing ER stress 












that for one of the two mAbs studied, harvest day has a pronounced impact on formulated 
mAb stability, as determined by SVP formation. More specifically, we show that mAb A 
material from an early (day 9) harvest, when ER stress is lower, forms significantly fewer 
SVPs than that from a late (day 13) harvest, when biomarkers of ER stress are elevated.  
2 Materials and Methods 
2.1 Cell Culture 
Two MedImmune suspension CHO cell lines, each expressing a model monoclonal antibody 
(mAb) were used in this study. For the purposes of this study these are denoted as cell line A 
which produced mAb A, an IgG1, and cell line B which produced mAb B, an IgG2. To 
generate material for mRNA profiling and stability studies, un-fed batch and fed-batch 
cultures were run for each cell line using MedImmune proprietary media and feed. Cultures 
were seeded at a concentration of 0.5 x106 viable cells/mL and maintained in roller bottles 
(Coring, USA) under the following conditions; shaking at 140 rpm, 70% relative humidity 
and 4% CO2. Half of the fed-batch cultures were harvested on day 9 of culture (denoted early 
harvest) and the remaining harvested on day 13 (denoted late harvest). Supernatant material 
was harvested by centrifugation at 10,000 x g for 20 minutes at 4oC. Cell concentrations and 
culture viability were determined daily using the trypan blue exclusion method on a ViCell 
Beckman Coulter instrument (CA).  
2.2 Determination of Monoclonal Antibody Concentrations 
Concentrations were determined using protein A HPLC as previously reported [29].  
2.3 Sampling of Cells for mRNA and Protein Analysis 
Viable cell pellets of 2x106 or 1x107 cells were collected for mRNA and protein analysis 
respectively on each day of culture from day 3 onwards. Cells were sampled by centrifugation 












2.4 Purification of Monoclonal Antibody from Cell Culture Supernatant 
mAb material was purified using protein A chromatography following MedImmune’s in-
house protocol which utilizes a low pH elution step. The pH of the eluted material was 
adjusted to pH 5.5 and 0.22 µm sterile filtered under vacuum (Millipore). All material was 
then stored at -80oC.  
2.5 Formulation of Protein A Purified mAb Material 
The purified mAb material was thawed and buffer exchanged using centrifugal concentrators 
(Millipore) into two buffers. mAb A material was buffer exchanged into either 20 mM 
histidine, 160 mM arginine-HCl, pH 6.0 or 20 mM histidine, 80 mM arginine-HCl, 120 mM 
sucrose, pH 6.0. MAb B material was buffer exchanged into either 20 mM histidine, 80 mM 
arginine-HCl, pH 6.0 or 20 mM histidine, 240 mM sucrose, pH 6.0. The material was then 
concentrated to 20 mg/mL and 0.22 µm sterile filtered (Millipore) before aliquoting 1.5 mL 
into 3 mL glass vials. Formulations used in this study were selected based upon previous 
work and knowledge of the selected IgGs at MedImmune.  
2.6 mAb Accelerated Stability Studies and Analysis 
Stability was assessed by measuring soluble aggregate, fragment and SVP levels of mAb 
formulations after storage under accelerated temperature conditions (40oC). Vials were 
analysed at T=0 then after 1 and 3 months incubation. 
2.7 Sub-visible Particle Counting 
Micro Flow Imaging (MFI) was carried out using a MFI 5200 (Protein Simple) to count SVPs 
in formulated mAb samples ranging in size from 1 to 100 μm. Prior to analysis, the MFI 
system was primed with 150 μL of sample, then 500 μL of sample analysed. An aspect ratio 












2.8 Analysis of Soluble Aggregate, Fragment and Monomeric Species 
mAb samples were analysed for monomer, aggregate and fragment content using isocratic 
Size Exclusion High Performance Liquid Chromatography (SEC-HPLC) using a TSKgel 
G3000SWXL column (Tosoh Bioscience) attached to an Agilent HPLC 2100 system. 25 μL 
of each sample was injected, and the absorbance monitored at 280 nm. The resultant 
chromatograms were integrated to establish the percentage of soluble aggregate, monomer 
and fragment species present.  
2.9 Total RNA Extraction and DNAse Treatment 
Cell pellet samples were thawed into RLT buffer (Qiagen) and RNA extracted using an 
RNeasy kit with shredder columns and on column DNAse treatment (Qiagen). The eluted 
RNA was diluted to a concentration of 25 ng/μL. 
2.10 mRNA Expression Analysis by qRT-PCR  
Qiagen QuantiFast SYBR Green RT-PCR kits were used for qRT-PCR as previously 
described [30]. The expression for each gene of interest (GOI) was then compared to that of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an endogenous control, and the 
change in expression of each sample calculated using the ∆∆Ct method [31]. An average ∆∆Ct 
across biological repeats was established and normalised to day 3 samples to calculate a fold 
change in expression for each GOI. Linear regression analysis was then carried out using 
Minitab17 software (version 17.3.1) to assess the relationship between sample day and fold 
change in GOI expression. The R2 value and statistical significance (P <0.05) of this 
relationship was determined for each transcript. To assess HC and LC transcript copy 
numbers a standard curve was generated, using plasmid DNA as the template, to extrapolate 
transcript copy numbers from. Primer sequences used for qRT-PCR experiments are listed in 












studies [12, 27-28] that also used qRT-PCR to analyse the fold change of genes related to ER 
stress. 
2.11 Western Blotting to Determine Intracellular HC and LC Protein Expression 
Cell pellets were re-suspended in 2 mL of lysis buffer as described by Mead et al [30]. Equal 
volumes of cell lysate from each sample were then analysed by SDS-PAGE using a standard 
protocol [32]. A ‘wet blotting’ technique was used to transfer proteins onto a nitrocellulose 
membrane. Membranes were blocked using 5% w/v milk powder in Tris-buffered saline 
before washing the membrane and addition of an appropriate horseradish peroxidase (HRP) 
conjugated primary antibody (anti-human IgG or anti-human lambda light chain, The Binding 
Site, both diluted 1:20,000) for chemiluminescence detection. Membranes were incubated in 
primary antibody solution for 18 hours at 4oC. Densitometry analysis of bands was performed 
using ImageJ 1.50i software [33]. Sample loading was normalised to total protein expression 
using corresponding Coomassie stained gels (Supplementary Figure 3).  
3 Results 
A number of studies have assessed changes in gene expression profiles throughout culture of 
IgG producing CHO cell lines [34]. Of particular relevance to the work reported here are 
those that report changes in gene expression related to UPR and ERAD pathways. For 
example, Prashad and Mehra [27] compared the mRNA expression of 17 genes within these 
pathways between high and low recombinant protein producing cell lines grown under batch 
conditions. A more comprehensive study by Maldonado-Agurto and Dickson [28] assessed a 
panel of 27 genes throughout batch culture and investigated the impact of prolonged cell 
culture on the UPR and ERAD pathways, as well as evaluating the impact of chemically 
induced ER stress. Both studies showed that during prolonged batch culture, cells experience 
increased ER stress as culture duration progressed. Surprisingly, there has been little work 












fact that it is known that cellular stress can impact on the quality of recombinant protein 
produced. We have therefore compared the profile of key UPR and ERAD transcripts 
between batch and fed-batch conditions of mAb producing CHO cell lines to determine the 
degree of such stress perceived by the cell during culture. Importantly, we have then related 
these biomarker profiles to the subsequent stability of Protein A purified mAb harvested at 
different stages of culture, when the cells were under different UPR and ERAD stress as 
determined from the transcript profiles.  
3.1 Analysis of mAb Producing CHO Cell Line Growth and Productivity Characteristics 
To compare the UPR and ERAD response of the model cell lines between fed and batch 
conditions, and to generate mAb material harvested at different points of culture, 6 fed-batch 
and 2 batch cultures were run for each cell line. Under batch culture conditions, the two cell 
lines had similar growth profiles, product yields and cell specific productivities (Qp) (Figure 
1 and Supplementary Table 2). Both cell lines reach a maximum average viable cell 
concentration on day 6 of culture, being 9.6 x106 cells/mL for cell line A and 10.0 x106 
cells/mL for B. After this point, both cell lines entered a decline phase with culture viabilities 
dropping from 92% on day 6 to 81% on day 7 for A, and 92% to 72% for B. By day 10 of 
culture, when the cultures were terminated, viabilities were 25% and 41% for A and B 
respectively (Figure 1). The majority of the material was produced over the first 7 days with 
only a small increase in product yield after an additional 3 days of culture for both cell lines. 
Qp was similar between cell line A (0.7 pg/cell/day) and B (0.5 pg/cell/day) (Supplementary 
Table 2). 
The viable cell concentrations under fed-batch conditions for both cell lines were 
considerably higher than those under batch conditions. There was also a notable difference 
between growth profiles and mAb production for the two cell lines (Figure 1). Cell line A 
fed-batch cultures reached the end of growth phase on day 6, when cultures were 98% viable 












After this the number of viable cells declined, although the culture viability declined from day 
6 and was 50% when cultures were terminated on day 13. Although this is lower than might 
be used in a commercial industrial setting, this culture viability was considered appropriate 
for establishing whether there was a correlation between culture day/viability and the stability 
of the subsequent mAb material as assessed from the propensity to form SVPs.  
Cell line B reached the end of growth phase one day later on day 7, but attained a much lower 
maximum viable cell concentration of 14.5 x106 cells/mL. This cell concentration was 
maintained in cell line B until the end of culture (Figure 1). On day 13, the culture viability 
had decreased to 61%. This difference in viable cell concentrations meant that the IVCD of 
cell line A over the 13 day fed-batch culture was approximately 1.35 times that of cell line B 
(Supplementary Table 2). With regard to mAb production, cell line A produced a titre of 2308 
mg/L on day 9 and 2907 mg/L on day 13, whilst cell line B had a titre of 1665 mg/L on day 9 
and 2445 mg/L on day 13 (Supplementary Table 2). Thus 79% of total mAb material was 
produced in the first 9 days of culture for cell line A, whilst 68% of the material in cell line B 
was produced in the first 9 days. Further, although the overall yield of mAb from cell line A 
was higher than cell line B, under fed-batch conditions, the Qp of cell line B was 1.7x that of 
cell line A (14.2 pg/cell/day compared to 8.3 pg/cell/day). 
3.2 Profiling of ER Stress mRNA Transcript Biomarkers  
In order to link upstream stress during synthesis of mAb in the cell with stability when 
formulated and harvest day, it was necessary to first establish that the model cell systems here 
did indeed perceive different levels of stress throughout culture. It is well established that 
increased recombinant protein production can contribute to ER stress [11, 14, 27, 28, 35], we 
therefore assessed ER stress in our model cell lines throughout culture using qRT-PCR to 
monitor the expression of 11 genes (summarised in Table 1) as ‘biomarkers’ of ER stress 
relative to the expression of glyceraldehyde 3-phosphate dehydrogenase. We then analysed 












relationship between two variables (Supplementary Figure 1). A change in the amount of a 
target transcript was considered statistically significant when p <0.05, with the results being 
compared between culture conditions (fed-batch and batch) and cell lines. All significantly 
changing genes were found to be upregulated as cultures progressed, indicating increased ER 
stress. 
More ER biomarker transcripts were found to be significantly upregulated in expression over 
culture under batch conditions than fed-batch (5 for batch and 4 for fed in cell line A, 7 and 3 
respectively for cell line B, Table 1). In both cell lines, the expression of atf4, ragc and rpn1 
transcripts was significantly increased during batch cultures compared to fed-batch cultures. 
Chac1 and hspa9 expression was also significantly increased as culture progressed under 
batch conditions compared to fed-batch in cell line B cultures but not cell line A. Therefore, 
the number of ER stress related genes significantly upregulated in batch samples compared to 
fed-batch was increased, indicating that cells grown under batch conditions were under 
greater ER stress than those cultured under fed conditions.  
Under fed conditions, calreticulin and herpud1 were the only two ER biomarker transcripts 
that significantly increased in expression throughout culture for both cell lines A and B. A 
significant increase in bip and hsp90b expression was observed in cell line A only under fed-
batch conditions, while derl3 expression increased in cell line B only. The magnitude of the 
change of each of these transcripts is depicted in Supplementary Figure 2. 
3.3 Analysis of mAb Heavy and Light Chain Expression at the Transcript and Protein 
Level  
The abundance of HC and LC transcripts and polypeptides within CHO cell lines producing 
IgGs has previously been investigated [27, 28], with some groups establishing a relationship 
between increased HC:LC ratios and productivity [36-40] and other studies linking HC:LC 












stress, as excess HC polypeptides are retained in the ER for re-folding or degradation by 
molecular chaperones such as BiP and Hsp90b if they are unable to assemble with the LC 
[42]. As we wished to link industrially relevant upstream cellular stress with formulated mAb 
stability, we therefore investigated fed-batch culture samples for HC and LC intracellular 
expression at the transcript and polypeptide level. 
HC:LC transcript copy number ratios were analysed between cell lines A and B under fed and 
batch conditions (Figure 2 and Supplementary Table 3). For cell line A, HC transcript 
numbers were significantly higher than those for the LC on every sample day under batch and 
fed-batch conditions, with the exception of day 13 for fed-batch cultures (Figure 2). Fed-
batch HC transcript numbers peaked on day 9 at 2.9 x104 transcripts per cell compared to the 
LC which also peaked on day 9 at 6.1 x103 transcripts per cell. Batch culture HC transcript 
numbers reach a maximum of 1.5 x104 transcripts per cell on day 6, when LC transcript 
numbers were low. Cell line B on the other hand, had greater LC transcript numbers than HC 
under both fed and batch conditions. Thus, cell line A had a much higher amount of HC 
mRNA than LC, whilst cell line B had a higher amount of LC transcript than HC (Figure 2). 
Intracellular polypeptide amounts were analysed by western blotting which allows relative 
changes in HC or LC to be assessed throughout culture and between the two cell lines using 
densitometry (Figure 3). The profile of intracellular HC expression at the polypeptide level 
during fed-batch culture (Figure 3) was consistent between the two cell lines throughout 
culture. HC expression increased for both cell lines approximately 7-fold by day 13 of culture 
relative to day 3. There was no significant change in HC polypeptide expression between 
days 6, 7 and 8 however, a significant fold change was observed between days 8 and 9 for 
both cell lines. There were obvious differences in LC polypeptide expression during fed-batch 
culture between the two cell lines. Cell line B showed a greater change in the amount of LC 












polypeptide expression between days 8 and 9 of culture in cell line B which was not observed 
in cell line A samples (Figure 3). 
Differences between HC and LC transcript expression in the two cell lines was partially 
reflected at the polypeptide level, with LC transcript amounts, and the increase in LC 
polypeptide throughout culture compared to day 3, higher in cell line B than cell line A. This 
was less pronounced for the relationship between HC transcript copy numbers and HC 
intracellular polypeptide. Although there was more HC transcript in cell line B than A, the 
change in HC polypeptide compared to day 3 in both cell lines showed a similar increase 
between day 8-9, even though HC transcript numbers were similar across days 6-10 of culture 
(Figure 3). Comparing the polypeptide and transcript data for cell line A, HC transcript 
numbers were consistently higher than LC, however at the polypeptide level it was only from 
day 9 that HC expression was higher than earlier days. Further, for early harvest material (day 
9), intracellular HC amounts at the polypeptide level increased similar to that of the LC up to 
this point, compared to the late harvest (day 13), for which HC amounts were elevated from 
day 9 compared to earlier days (Figure 3). For mAb B, generated from cell line B, that did not 
show an increase in particle numbers with harvest day (see below), there was less variation in 
HC or LC transcript (or polypeptide) amounts between the two harvest days. 
3.4 Effect of Harvest Day during Fed-Batch Culture on Monoclonal Antibody Stability 
The main focus of this study was to investigate whether a relationship exists between 
increased intracellular ER stress experienced during CHO cell culture, day of harvest and 
formulated product stability. As the model cell lines used in this study did show differences in 
both ER stress responses and HC/LC expression throughout culture, we set out to determine if 
these observations related to the stability of formulated mAbs as determined by the propensity 
of the material harvested at different times throughout culture to form SVPs. We thus 
investigated mAb stability by evaluating soluble aggregate, fragment and SVP formation over 












aggregate formation may cause autoimmune responses in patients, and the formation of such 
species can also impact on product efficacy [6, 43-45]. Due to such concerns, regulatory 
authorities request that manufacturers of therapeutics such as mAbs report SVP levels in their 
drug products. The current specifications require that particles greater than 10 µm and 25 µm 
are reported (United States Pharmacopoeia <788>). Particles less than 10 µm are currently 
not required to be monitored, however their significance in autoimmune responses and 
product quality is an area of significant debate [8, 46-49]. The emergence of technologies 
such as MFI enable monitoring of particles as small as 1 µm, and we therefore report SVPs in 
the range of 1-100 µm in size.  
To investigate whether harvest day (and therefore differing levels of ER culture stress) 
impacts on soluble aggregate, fragment and SVP formation, mAb material from an early (day 
9) and late (day 13) harvest was purified and formulated in two different buffers. Particle 
analysis for mAb A (Figure 4) showed material from the late day 13 harvest consistently had 
higher numbers of particles relative to the samples harvested on day 9. This was observed 
across all time points, buffers and particle size ranges. Furthermore, the mAb A material 
which was formulated in 80 mM arginine-HCl, 120 mM sucrose had higher numbers of 
particles compared to when formulated in 160 mM arginine only. As both arginine and 
sucrose stabilise proteins through different mechanisms, it is unclear from this data whether 
this observation is down to a stabilising effect of increased arginine-HCl concentrations or 
due to the absence of sucrose. To complement SVP data, we also undertook SEC-HPLC 
analysis, however this revealed no change in monomer, soluble aggregate or fragment levels 
across the different harvest day or formulations (Supplementary Table 4). 
Conversely, mAb B material showed no relationship between harvest day and particle 
amounts across size ranges, time points or formulations although generally there were higher 
numbers of particles for mAb B samples than mAb A material. As for the mAb A SEC-HPLC 












over time across the different harvest day or formulations for mAb B material 
(Supplementary Table 4). 
4 Discussion 
Although previous studies have reported ER stress mRNA biomarker profiles within CHO 
cell cultures producing IgG molecules under batch culture conditions, and have reported on 
HC and LC mRNA/protein expression and the relationship between HC:LC ratios and Qp 
[27, 28, 36], surprisingly these observations have not been related to the product stability later 
in the bioprocess, particularly when formulated in a drug product format. A number of studies 
have begun bridging the gap between upstream cell culture performance and product quality, 
analysing the impact of increased HC expression on aggregate formation [40, 41]. However, 
only one study to our knowledge reports biomarker profiles for cells cultured under fed-batch 
conditions [12], and there are no studies that investigate the stability of the subsequent 
purified mAb material when formulated and subjected to accelerated stability studies such as 
those routinely used during formulation development. We therefore set out to bridge this gap 
by relating ER perceived cell stress with harvest day and stability of the subsequent purified 
mAb as determined by determining the propensity of the material to form particles under 
accelerated stability study conditions.  
The mAb stability data presented here shows a relationship between observations at the 
molecular level with regard to perception of ER stress and intracellular HC/LC transcript and 
polypeptide ratio during fed-batch culture and the propensity of formulated mAb to form 
SVPs under temperature stress conditions. Specifically, we show that for one of the cell lines 
investigated (cell line-A), fed-batch mAb material harvested on day 9 of culture is more 
stable, in terms of SVP formation, than for material harvested from day 13 of culture. The 
second cell line investigated, (cell line B) on the other hand, showed no trend regarding the 












When analysing the growth and productivity, mRNA biomarker profiles and HC/LC 
polypeptide and transcript data between the two harvest days for cell line A, there are several 
observations which may account for the differences observed in stability at different harvest 
days. Firstly, there is an increase in the amount of intracellular HC in cell line A later in 
culture. Associated with this is a significant increase in BiP and Hsp90b expression over 
culture in cell line A only, suggesting that cells harvested on day 13 of culture were under 
elevated ER stress compared to day 9 and that mAb made between days 9-13 was done so 
under elevated intracellular stress conditions. BiP binds polypeptides as they enter the ER and 
will bind both the LC and HC of an IgG. Whilst LC can fold independently of the HC, the 
folding of the heavy chain CH1 domain requires association with a folded LC that displaces 
bound to BiP as folding occurs and the HC and LC associate [42]. In the event of excess HC 
polypeptide expression, BiP and Hsp90b therefore function to retain the HC in the ER 
maintaining this in a state for association with the LC or directing excess polypeptide for 
degradation [18, 42].  
When evaluating this data in combination with the observation of high HC:LC (>2) transcript 
ratios and low Qp, it is not surprising to see significantly elevated Bip and Hsp90b expression 
in cell line A as cultures progress, with such stress likely to be underpinned by the observed 
accumulation of excess HC polypeptide in the ER. Cells at the late harvest point (day 13) 
have therefore been under elevated ER stress for a longer period of time than cells from the 
early harvest on day 9. These observations at the molecular level during upstream culture 
suggest that ER stress, caused by high HC:LC mRNA ratios and an accumulation of HC 
polypeptide relate to an increase in SVP formation of mAb A material from the late (day 13) 
harvest. Thus, we propose that the upregulation of ER stress biomarkers is indicative of 
conditions under which synthesised mAb has a greater propensity to form SVPs. The ER 
stress markers themselves (discussed below) do not directly contribute to the formation of 
increased SVPs. Further, although the Qp of cell line A expressing mAb A was lower than 












changes in the transcripts of the ER biomarkers, we propose that the lower Qp of cell line A 
reflects the difficult to express nature of the mAb A molecule that places an increased load on 
the ER and results in reduced mAb secretion. 
Cell line B elicited a different ER stress response to cell line A, also providing a rationale for 
the mAb A showing a different propensity to form SVPs on different harvest days but not 
mAb B. The transcript for Derl3 significantly changed across culture in cell line B only and 
there was not a change in Bip or Hsp90b. Derl3 is a member of the Derlin family of proteins 
which respond as part of the ERAD pathway to maintain ER homeostasis through retro-
translocating misfolded or unfolded proteins from the ER into the cytosol for degradation [50, 
51]. Derl3 expression increased from day 8 of culture onwards (Supplementary Figure 2), 
meaning that Derl3 expression was elevated at both the early and late harvests. This suggests 
that cell line B acts upon perceived ER stress sooner than cell line A, and that through 
activating the ERAD pathway, is better able to cope with a high recombinant protein load. As 
a result, the cell line maintains a higher culture viability (61% on day 13 for cell line B 
compared to 50% for cell line A, Figure 1), a higher Qp and generates mAb material less 
prone to SVP formation. Moreover, cell line B consistently has low HC:LC transcript ratios, 
meaning there was excess LC to drive HC folding and mAb assembly. 
As expected, biomarker profiling also showed that batch cultures perceive greater ER stress 
than fed-batch, with more genes significantly changing in expression for batch cultures than 
for those that were fed (Table 1). When grown under batch culture conditions, the two cell 
lines elicit very similar growth profiles and give similar mAb productivities. Biomarker 
monitoring reflects these observations, with 4 common genes significantly changing over 
time between the two cell lines under batch conditions, compared to just 2 for fed-batch. Fed-
batch conditions therefore enable molecular differences between cell lines to be determined 
which, under batch conditions, are not observed. Further, the different cell lines and mAb 












purification process. Host cell protein content would be expected to increase at the later time 
point and can be cell line specific, providing a possible explanation as to why there is no ER 
stress biomarker correlation for cell line B.  
Finally, we asked what impact these observations could have on upstream culture decisions 
with regard to harvest day, that subsequently influence the stability of the mAb in the final 
product. Generally, CHO cultures producing recombinant proteins, such as mAbs, will run 
either until a set number of days have passed or until culture viability drops below a 
predefined threshold. Our data, however, shows that in the case of cell line A, material 
harvested earlier in culture when perceived ER stress is lower is less prone to forming 
particles than that harvested later in culture when increased ER stress is perceived. We 
therefore propose that cellular stress biomarker profiles could be incorporated into cell line 
development and fed-batch culturing strategies to identify culturing strategies and a day of 
harvest that maximises product yield and formulated mAb stability, rather than rely on setting 
a harvest day based on culture longevity or viability alone. The work reported here has shown 
that the use of ER stress biomarker profiles is cell line and/or product specific; and thus 
whether day of harvest has an impact on stability, and use of stress biomarkers, should be 
assessed for each molecule and cell line.  
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Table 1: Summary of Linear Regression Analysis for each gene of interest (GOI) and 
function of the corresponding proteins. Fold change in expression for each GOI was analysed 
using qRT-PCR, then used in linear regression analysis to build a model predicting how the 
GOI expression changed with culture conditions and day as a marker of ER stress. One-way 
ANOVA was then used to evaluate those genes of interest significantly change over culture, 
where * denotes a significance level of P <0.05, and ** denotes P <0.01. The fold change in 
expression increased throughout culture for all genes of interest. Data from days 3, 6, 7, 8, 9 
10 and 13 were analysed for fed samples, and days 3, 4, 5, 6 and 7 for batch. 
Gene of 
Interest Encoded Protein Function 
Cell Line A Cell Line B 
Fed Batch Fed Batch 
ATF4 
Transcription factor reported to 
enhance the expression of UPR 






Hsp70 molecular chaperone, 
functioning to retain proteins in the 





Functions as a chaperone to aid 
folding of glycoproteins, as well as 
being involved in calcium storage 
in the ER 
* ** ** 
 
Chac1 
Pro-apoptotic protein which 
functions as part of the UPR; 
expression of chac1 is activated by 
ATF4    
* 














functions as part of the ERAD 
response to translocate misfolded 
proteins for degradation 
HerPud1 
Functions as part of the ERAD 







Member of the heat shock family 
of proteins, functions sequentially 
with BiP as a chaperone to aid the 
folding of proteins 
* 
   
Hspa9 Hsp70 family member, found in the mitochondria and ER 
   
* 
Pfdn2 
One of four beta subunits which 
comprise Prefoldin; a chaperone 
which assists the folding of newly 
synthesised polypeptides     






Forms part of the regulatory 26S 
Proteasome subunit and is therefore 


















Figure 1. Growth Characteristics of Cell Lines Under Fed-Batch and Batch 













Figure 2. HC and LC Transcript Copy Numbers Produced in Cells Under Fed-batch and Batch 
Conditions. Cell line A fed-batch (A) and batch (B) cultures; and cell line B fed-batch (C) and 
batch (D). Copy numbers were established using qRT-PCR with a DNA standard curve. Solid 
bars show heavy chain transcript copy numbers, and striped bars show the light chain. Error 
bars are the mean +/- one standard deviation. 
 













Figure 4. Sub-Visible Particle Formation of Formulated mAb Determined by MFI 
Analysis. Sub-visible particle counts per mL of (A) mAb A, where darker bars represent 
material formulated in 20 mM histidine, 80 mM arginine-HCl, 120 mM sucrose, pH 6.0 and 
lighter bars represent 20mM histidine, 160 mM arginine-HCl, pH 6.0. Striped bars represent 
material from the day 13 harvest and solid bars from the day 9 harvest. Figure (B) are sub-
visible particle counts for mAb B samples, where darker bars represent material formulated in 
20 mM histidine, 240 mM sucrose, pH 6.0 and lighter bars represent material formulated in 
20 mM histidine, 80 mM arginine-HCl, 120 mM sucrose. Striped bars show material from a 
day 13 harvest and solid bars represent the day 9 harvest. Samples were analyzed at T=0 and 
after 1 month and 3 months incubation at 40oC. 
